NAYA Biosciences announces new data for its Flex-NK bispecific antibody

NAYA Biosciences, a company which has recently signed a definitive merger agreement with INVO Bioscience to establish an expanded, publicly-traded life science company, announced that new data for its CD38-targeted Flex-NK Bispecific Antibody for the treatment of Multiple Myeloma (MM) was published as an abstract in the 2023 American Society of Hematology’s meeting supplement of Blood, in the “Multiple Myeloma: Prospective Therapeutic Trials” section. “NAYA is building a portfolio of differentiated clinical-stage oncology therapeutics, starting with two FLEX-NK(TM) bispecific antibodies acquired from Cytovia Therapeutics,” commented NAYA CEO Dr. Daniel Teper. “We are excited about this new data for our CD38-targeted antibody, which aims to address limitations with the current standard-of-care and offer new options for multiple myeloma patients.”